343 related articles for article (PubMed ID: 32620200)
1. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
Schlesinger N; Lipsky PE
Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
[TBL] [Abstract][Full Text] [Related]
2. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Mandell BF; Yeo AE; Lipsky PE
Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
[TBL] [Abstract][Full Text] [Related]
3. Pegloticase for treating refractory chronic gout.
George RL; Sundy JS
Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
[TBL] [Abstract][Full Text] [Related]
4. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
[TBL] [Abstract][Full Text] [Related]
5. Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.
Keenan RT; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2022 May; 40(5):1006-1010. PubMed ID: 35238750
[TBL] [Abstract][Full Text] [Related]
6. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA
Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509
[TBL] [Abstract][Full Text] [Related]
7. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
[TBL] [Abstract][Full Text] [Related]
8. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTORâ„¢) versus pegloticase for refractory gout.
Baraf HSB; Khanna PP; Kivitz AJ; Strand V; Choi HK; Terkeltaub R; Dalbeth N; DeHaan W; Azeem R; Traber PG; Keenan RT
Rheumatology (Oxford); 2024 Apr; 63(4):1058-1067. PubMed ID: 37449908
[TBL] [Abstract][Full Text] [Related]
9. Development of a multivariable improvement measure for gout.
Schlesinger N; Edwards NL; Yeo AE; Lipsky PE
Arthritis Res Ther; 2020 Jun; 22(1):164. PubMed ID: 32600452
[TBL] [Abstract][Full Text] [Related]
10. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
[TBL] [Abstract][Full Text] [Related]
11. [Gout: an overview of available urate lowering therapies].
Richette P
Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
[TBL] [Abstract][Full Text] [Related]
12. Pegloticase: in treatment-refractory chronic gout.
Lyseng-Williamson KA
Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and treatment of gout as a chronic disease.
Perez-Ruiz F; Herrero-Beites AM
Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
[TBL] [Abstract][Full Text] [Related]
14. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
[TBL] [Abstract][Full Text] [Related]
15. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
Johnson RJ; Choi HK; Yeo AE; Lipsky PE
Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535
[TBL] [Abstract][Full Text] [Related]
16. Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
Pillinger MH; Fields TR; Yeo AE; Lipsky PE
J Rheumatol; 2020 Apr; 47(4):605-612. PubMed ID: 31203212
[TBL] [Abstract][Full Text] [Related]
17. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.
Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; Song Y; LaMoreaux B; Zhao L; Xin Y; Chamberlain J; Ramanathan S; Weinblatt ME; Peterson J
Arthritis Res Ther; 2022 Aug; 24(1):208. PubMed ID: 36008814
[TBL] [Abstract][Full Text] [Related]
18. Pegloticase for treatment of tophaceous polyarticular gout.
Seifried RM; Roberts J
Hawaii J Med Public Health; 2013 Jul; 72(7):220-3. PubMed ID: 23901393
[TBL] [Abstract][Full Text] [Related]
19. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
[TBL] [Abstract][Full Text] [Related]
20. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2014 Oct; (10):CD010069. PubMed ID: 25330136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]